Teva Pharmaceuticals to acquire BioXcel assets for up to $125m
The transaction would see Teva obtain worldwide rights to Igalmi and the investigational BXCL501.
Featured s
Myasthenia gravis market to reach $13.0bn across 7MM by 2034
MG treatment regimens are determined through the classification of a patient’s clinical status and autoantibody status.
All Articles
Teva Pharmaceuticals to acquire BioXcel assets for up to $125m
The transaction would see Teva obtain worldwide rights to Igalmi and the investigational BXCL501.
Myasthenia gravis market to reach $13.0bn across 7MM by 2034
MG treatment regimens are determined through the classification of a patient’s clinical status and autoantibody status.
Lilly’s Mounjaro wins US label expansion for cardiovascular risk reduction
The approval will likely expand Lilly’s cardiometabolic empire as it looks to stay ahead of rival Novo Nordisk.
FDA approves Priovant’s rare autoimmune therapy Lisraya in indication first
The biotech is now looking to roll out Lisraya, the first targeted therapy for dermatomyositis, across the US via specialty…
MSD’s Lipfendra takes on injectable rivals for cholesterol-lowering market supremacy
Armed with oral administration and a cheaper price tag, Lipfendra is touted as a major advancement for patients.
AusperBio raises $120m to progress hepatitis B therapies
AusperBio’s total capital raised since 2024 has reached $360m.
FDA to review Kowa Pharmaceuticals’ NDA for glaucoma eye drop K-911
The NDA is supported by two pivotal Phase III trials comparing K-911 0.1% with latanoprost 0.005%.
SK inks $795m Biohaven epilepsy deal, entering potassium channel opener race
SK and Biohaven hope opakalim will show differential benefit to Xenon’s rival focal epilepsy drug, azetukalner, in an upcoming pivotal…
ESC 2026: True impact of poor medicine adherence laid bare in hypertensive patients
Study shows that those with low adherence of blood pressure-lowering drugs had significantly impaired therapeutic effect.
FDA grants RPDD to ReviR’s RTX-117 for CMT
The designation covers CMT as a whole and is not restricted to specific subtypes.